Who is sponsoring NCT02929095?

NCT02929095 is sponsored by Yonsei University.

What drugs are being tested in NCT02929095?

Interventions in NCT02929095: dexmedetomidine, midazolam, remifentanil.

What condition does NCT02929095 study?

NCT02929095 studies Peripheral Arterial Occlusive Disease.

Is NCT02929095 still recruiting?

NCT02929095 is currently completed. Last updated 10 January 2019.

Last reviewed 2019-01-10 · How we verify

NCT02929095

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

The Effect of Remifentanil-dexmedetomidine Compared With Remifentanil-midazolam on Patient's Satisfaction

Completed NA Last updated 10 January 2019

What this trial tests

NA trial testing dexmedetomidine in Peripheral Arterial Occlusive Disease in 70 participants. Completed in 2 April 2018.

Timeline

1 October 2016

Primary endpoint
2 April 2018

2 April 2018

Quick facts

Lead sponsor	Yonsei University
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	double
Primary purpose	prevention
Enrollment	70
Start date	1 October 2016
Primary completion	2 April 2018
Estimated completion	2 April 2018
Sites	1 location across South Korea

Drugs / interventions tested

dexmedetomidine (dexmedetomidine) — full drug profile →
midazolam (midazolam) — full drug profile →
remifentanil — full drug profile →

Conditions studied

Peripheral Arterial Occlusive Disease — all drugs for Peripheral Arterial Occlusive Disease →

Sponsor

Yonsei University

Who can join

Adults 20 to 79, male only, with Peripheral Arterial Occlusive Disease. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Percutaneous trans-arterial angioplasty(PTA) is one of the peripheral arterial occlusive disease(PAOD) treatment. During and after PTA, ischemia-reperfusion pain is induced so proper analgesia is important. ischemia-reperfusion injury is due to reactive oxygen species. Dexmedetomidine has analgesic, sedative and anti oxidant effect. So the investigators research the patient's satisfaction that are given the dexmedetomidine during PTA procedure.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

TrialBench: Multi-Modal AI-Ready Datasets for Clinical Trial Prediction.
Chen J, Hu Y, Cai M, Lu Y, et al · · 2025 · cited 1× · PMID 41006354 · DOI 10.1038/s41597-025-05680-8

Verify or expand the search:

Other trials of dexmedetomidine

Trials testing the same drug.

NCT06853431 — Determination of ED50 and ED95 With Clinical Efficacy of Intranasal Dexmedetomidine Combined With Esketamine for Preoper · Phase 4 · recruiting
NCT06702488 — Dexmedetomidine and Magnesium Sulfate in the Reduction Cognitive Dysfunction in Geriatrics · Phase 1 · recruiting
NCT06636578 — Dexmedetomidine Ropivacaine Versus Plain Ropivacaine in Bilateral Pectoralis Nerve (PECS) Block · Phase 4 · recruiting
NCT07510217 — ERAS Approach for Post-Craniotomy Headache and Psychological Recovery · Phase 2 · completed
NCT06498700 — Intraoperative Subanesthetic Ketamine Versus Dexmedetomidine Infusion for Prevention of Post-traumatic Stress Disorder A · NA · enrolling by invitation

Other recruiting trials for Peripheral Arterial Occlusive Disease

Currently open trials in the same condition.

NCT07352800 — Safety of Antithrombotic Heparin Proteoglycan Mimetic APAC in Peripheral Arterial Occlusive Disease and Chronic Limb-thr · Phase 2 · recruiting
NCT05933720 — Efficacy and Safety of the Regulatory Polypeptides in Patients With Peripheral Atherosclerosis. · NA · recruiting

Other Yonsei University trials

Trials by the same sponsor.

NCT07547592 — Gemcitabine and Docetaxel With or Without Bevacizumab (Onbevzi) for Soft Tissue Sarcoma · Phase 2 · not yet recruiting
NCT07524101 — Moderate-Intensity Statin Plus Ezetimibe in CKD and ASCVD · NA · not yet recruiting
NCT07506629 — Adductor Canal Block Methods in Bilateral Total Knee Arthroplasty · NA · not yet recruiting
NCT07515716 — Effects of High Flow Humidified Oxygen on Umbilical Artery Acid-base Balance in Cesarean Section Under Spinal Anesthesia · NA · not yet recruiting
NCT07507188 — Collaborative Clinical-translational Cohort of Amivantamab Plus Lazertinib and Amivantamab Plus Chemotherapy in Patients · Phase 2 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT02929095 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Yonsei University
Last refreshed: 10 January 2019

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02929095.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing